The GO biological process and KEGG signalling pathway enrichment analysis for these targets predicted that DHLP could regulate MAPK1, STAT3, AKT1, MAPK8, TNF, and other targets and that DHLP could regulate TNF, toll-like receptor, HIF-1, and other signalling pathways as well as osteoclast differentiation to suppress inflammation and to regulate immune function to treat RA. The gene discussed is MAPK1; the disease is rheumatoid arthritis.